Imagion Biosystems Ltd (AU:IBX) — Market Cap & Net Worth
Market Cap & Net Worth: Imagion Biosystems Ltd (IBX)
Imagion Biosystems Ltd (AU:IBX) has a market capitalization of $5.90 Million (AU$8.34 Million) as of May 2, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28035 globally and #1515 in its home market, demonstrating a -5.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imagion Biosystems Ltd's stock price AU$0.02 by its total outstanding shares 490590239 (490.59 Million). Analyse Imagion Biosystems Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Imagion Biosystems Ltd Market Cap History: 2017 to 2026
Imagion Biosystems Ltd's market capitalization history from 2017 to 2026. Data shows change from $1.28 Billion to $5.90 Million (-47.76% CAGR).
Imagion Biosystems Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imagion Biosystems Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.00x
Imagion Biosystems Ltd's market cap is 3.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.28 Billion | $20.10K | -$7.79 Million | 63677.94x | N/A |
| 2018 | $392.74 Million | $191.48K | -$8.35 Million | 2051.09x | N/A |
| 2019 | $327.30 Million | $410.85K | -$3.43 Million | 796.64x | N/A |
| 2020 | $2.01 Billion | $205.72K | -$5.36 Million | 9786.83x | N/A |
| 2021 | $1.06 Billion | $232.87K | -$6.02 Million | 4531.62x | N/A |
| 2022 | $333.24 Million | $473.43K | -$9.81 Million | 703.88x | N/A |
| 2023 | $123.23 Million | $1.08 Million | -$12.47 Million | 113.79x | N/A |
| 2024 | $7.98 Million | $2.67 Million | -$2.07 Million | 3.00x | N/A |
Competitor Companies of IBX by Market Capitalization
Companies near Imagion Biosystems Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Imagion Biosystems Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Imagion Biosystems Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Imagion Biosystems Ltd's market cap moved from $1.28 Billion to $ 5.90 Million, with a yearly change of -47.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$5.90 Million | -32.00% |
| 2025 | AU$8.68 Million | +8.70% |
| 2024 | AU$7.98 Million | -93.52% |
| 2023 | AU$123.23 Million | -63.02% |
| 2022 | AU$333.24 Million | -68.42% |
| 2021 | AU$1.06 Billion | -47.59% |
| 2020 | AU$2.01 Billion | +515.12% |
| 2019 | AU$327.30 Million | -16.66% |
| 2018 | AU$392.74 Million | -69.32% |
| 2017 | AU$1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Imagion Biosystems Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.90 Million USD |
| MoneyControl | $5.90 Million USD |
| MarketWatch | $5.90 Million USD |
| marketcap.company | $5.90 Million USD |
| Reuters | $5.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Imagion Biosystems Ltd
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more